Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens

Leila Family, PhD, Su-Jau Yang, Zandra Klippel, MD, Yanli Li, MD PhD, John H Page, MD ScD, Roberto Rodriguez, MD, Chun Chao, PhD

Blood (2015) 126 (23): 3257.

https://doi.org/10.1182/blood.V126.23.3257.3257

Published: 2015

Journal Articles

Incidence of Chemotherapy Induced Anemia in Patients Diagnosed with Solid Tumors

Hairong Xu, MD, PhD, Lanfang Xu, MS, John H Page, MD ScD, Olivia Sattayapiwat, MS, Roberto Rodriguez, MD, Chun Chao, PhD

Blood (2014) 124 (21): 4822.

https://doi.org/10.1182/blood.V124.21.4822.4822

Published: 2014

Journal Articles

Trends in Anemia Treatment Among Patients with Non-Myeloid Malignancies Treated with Chemotherapy

Chun Chao, PhD, Lanfang Xu, MS, Olivia Sattayapiwat, MS, John H Page, MD ScD, Kimberly Cannavale, Roberto Rodriguez, MD, Chet Bohac, Hairong Xu, MD, PhD

Blood (2014) 124 (21): 6007.

https://doi.org/10.1182/blood.V124.21.6007.6007

Published: 2014

Journal Articles

Chronic Comorbidities and Chemotherapy-Induced Febrile Neutropenia in Patients with Non-Hodgkin Lymphoma

Chun Chao, PhD, John H Page, MD, ScD, Roberto Rodriguez, MD, Su-Jau Yang, PhD, Julie Huynh, MD, Victoria M Chia, PhD

Blood (2012) 120 (21): 3671.

https://doi.org/10.1182/blood.V120.21.3671.3671

Published: 2012

Journal Articles

A Prospective Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft Vs. Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)

Zaid Al-Kadhimi, MD, Zartash Gul, MD, Roberto Rodriguez, MD, Wei Chen, PhD, Alice Mitchell, BS, Muneer H. Abidi, MD, Lois Ayash, MD, Abhinav Deol, MD, Lawrence G Lum, MD, DSc, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2011) 118 (21): 4551.

https://doi.org/10.1182/blood.V118.21.4551.4551

Published: 2011

Journal Articles

Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor

Tam Khuu, PharmD, Sepideh Shayani, PharmD, Joycelynne Palmer, PhD, Roberto Rodriguez, MD, Pablo Miguel Parker, David S. Snyder, MD, Vinod Pullarkat, Joseph Rosenthal, Auayporn P. Nademanee, David Senitzer, PhD, Ryotaro Nakamura, MD, Stephen J. Forman

Blood (2008) 112 (11): 797.

https://doi.org/10.1182/blood.V112.11.797.797

Published: 2008

Journal Articles

Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).

Margaret R. O’Donnell, MD, Anthony S. Stein, MD, Ryotaro Nakamura, MD, Marilyn L. Slovak, PhD, Nicole Tsai, PhD, Joycelynne Palmer, PhD, Roberto Rodriguez, MD, Ricardo Spielberger, MD, Eileen P. Smith, MD, David S. Snyder, MD, Pablo M. Parker, MD, Leslie Popplewell, MD, Vinod Pullarkat, MD, Chatchada Karanes, MD, Neil Kogut, MD, George Somlo, MD, Stephen J. Forman, MD

Blood (2007) 110 (11): 1089.

https://doi.org/10.1182/blood.V110.11.1089.1089

Published: 2007

Journal Articles

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

George Somlo, MD, Dajun Qian, PhD, Firoozeh Sahebi, MD, Neil Martin Kogut, MD, Roberto Rodriguez, MD, Pablo Miguel Parker, MD, Leslie Popplewell, MD, Amrita Krishnan, MD, Joycelynne Palmer, PhD, Anthony Selwyn Stein, MD, Ricardo Spielberger, MD, Jeffrey Schriber, MD, Joseph Alvarnas, MD, Warren Chow, MD, Auayporn Nademanee, MD, Jasmine M. Zain, MD, Margaret R. O’Donnell, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 3089.

https://doi.org/10.1182/blood.V108.11.3089.3089

Published: 2006

Journal Articles

The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.

Ryotaro Nakamura, MD, Roberto Rodriguez, MD, Auayporn Nademanee, MD, Joycelynne Palmer, PhD, David Senitzer, PhD, David Snyder, MD, Jasmine Zain, MD, Vinod Pullarkat, MD, Stephen J. Forman, MD, Pablo Miguel Parker, MD

Blood (2006) 108 (11): 2866.

https://doi.org/10.1182/blood.V108.11.2866.2866

Published: 2006

Journal Articles

Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.

Roberto Rodriguez, MD, Joycelynne Palmer, PhD, Ryotaro Nakamura, MD, Pablo Miguel Parker, MD, Auayporn P. Nademanee, MD, David S. Snyder, MD, Vinod Pullarkat, MD, Jasmine M. Zain, MD, Ricardo Spielberger, MD, David Senitzer, PhD, Stephen J. Forman, MD

Blood (2006) 108 (11): 2867.

https://doi.org/10.1182/blood.V108.11.2867.2867

Published: 2006

Journal Articles

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

Amrita Krishnan, MD, Andrew Raubitschek, MD, Stephen J. Forman, MD, Henry Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter Falk, MD, Ricardo Spielberger, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Pablo Parker, MD, Warren Chow, MD, Ryoto Nakamura, MD, Auayporn Nademanee, MD

Blood (2005) 106 (11): 681.

https://doi.org/10.1182/blood.V106.11.681.681

Published: 2005

Journal Articles

Predictors of Avascular Necrosis (AVN) of Bone after Long-Term Follow-Up of Allogeneic and Autologous Hematopoietic Cell Transplantation (HCT) for Malignant and Non-Malignant Disorders.

Liton Francisco, BS, Stephanie Campbell, BS, Andrea Carter, BA, Roberto Rodriguez, MD, Joseph Rosenthal, MD, Carol Schroeder, R.N., Marianna Shakhnovits, MD, Stephen J. Forman, MD, Smita Bhatia, MD, M.P.H.

Blood (2005) 106 (11): 700.

https://doi.org/10.1182/blood.V106.11.700.700

Published: 2005

Journal Articles

Allogeneic Transplant with Standard Conditioning, Reduced Intensity, or Non-Myeloablative Conditioning Regimen for Multiple Myeloma (MM).

Firoozeh Sahebi, MD, Neil M. Kogut, MD, Ricardo Spielberger, MD, Peter M. Falk, MD, Auayporn P. Nademanee, MD, Leslie Popplewell, MD, David G. Maloney, MD, Roberto Rodriguez, MD, Amrita Krishnan, MD, Ryotaro Nakamura, MD, Margaret R. O’Donnell, MD, Parker M. Pablo, MD, Eileen P. Smith, MD, Anthony S. Stein, MD, David S. Snyder, M.D, Jasmine M. Zain, MD, Dajun Qian, Ph.D, Stephen J. Forman, MD, George Somlo, MD

Blood (2005) 106 (11): 5427.

https://doi.org/10.1182/blood.V106.11.5427.5427

Published: 2005

Journal Articles

Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.

Ryotaro Nakamura, MD, Joycelynne Palmer, PhD, Roberto Rodriguez, MD, Pablo Parker, MD, David Senitzer, PhD, Anthony Stein, MD, Josheph Rosenthal, MD, Sean Wang, MD, Jeffrey Schriber, MD, Stephen J. Forman, MD, Auayporn Nademanee, MD

Blood (2005) 106 (11): 2056.

https://doi.org/10.1182/blood.V106.11.2056.2056

Published: 2005

Journal Articles

Dose Intensity and Risk of Relapse for NHL after Allogeneic Transplant.

Roberto Rodriguez, MD, Auayporn Nademanee, MD, Nora Carter, Eileen Smith, MD, Amrita Krishnan, MD, Leslie Popplewell, MD, Jasmine Zain, MD, Mark Kirschbaum, MD, Allison Sano, RN, Kathy Patane, RN, Mudra Nathwani, CRA, Ricardo Spielberger, MD, Clarence Sarkodee-Adoo, MD, Stephen J. Forman, MD.

Blood (2004) 104 (11): 2311.

https://doi.org/10.1182/blood.V104.11.2311.2311

Published: 2004

Journal Articles

Evaluating the Clinical Efficacy of Increased Granulocyte Colony-Stimulation Factor (GCSF) in Patients Who Fail a Standard Dose Regimen during Peripheral Blood Stem Cell Collection.

Blood (2004) 104 (11): 2926.

https://doi.org/10.1182/blood.V104.11.2926.2926

Published: 2004

Journal Articles

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Henry C. Fung, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Zaid Al Kadhimi, MD, Mark Kirschbaum, MD, Neil Kogut, MD, Andrew Raubitschek, MD, Jeffrey Schriber, MD, Jasmine Zain, MD, Eileen Smith, MD, Nigel Cheng, Dajun Qian, PhD, Arturo Molina, MD, Stephen J. Forman, MD

Blood (2004) 104 (11): 5115.

https://doi.org/10.1182/blood.V104.11.5115.5115

Published: 2004

Journal Articles

Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.

Leslie L. Popplewell, MD, A. Nademanee, MD, Nora Carter, Jasmine Zain, MD, Amrita Krishnan, MD, Roberto Rodriguez, MD, Neil M. Kogut, MD, Nayana Vora, MD, Arturo Molina, MD, Stephen J. Forman, MD

Blood (2004) 104 (11): 894.

https://doi.org/10.1182/blood.V104.11.894.894

Published: 2004

NARROW

Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens

Incidence of Chemotherapy Induced Anemia in Patients Diagnosed with Solid Tumors

Trends in Anemia Treatment Among Patients with Non-Myeloid Malignancies Treated with Chemotherapy

Chronic Comorbidities and Chemotherapy-Induced Febrile Neutropenia in Patients with Non-Hodgkin Lymphoma

A Prospective Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft Vs. Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)

Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor

Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.

Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

Predictors of Avascular Necrosis (AVN) of Bone after Long-Term Follow-Up of Allogeneic and Autologous Hematopoietic Cell Transplantation (HCT) for Malignant and Non-Malignant Disorders.

Allogeneic Transplant with Standard Conditioning, Reduced Intensity, or Non-Myeloablative Conditioning Regimen for Multiple Myeloma (MM).

Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.

Dose Intensity and Risk of Relapse for NHL after Allogeneic Transplant.

Evaluating the Clinical Efficacy of Increased Granulocyte Colony-Stimulation Factor (GCSF) in Patients Who Fail a Standard Dose Regimen during Peripheral Blood Stem Cell Collection.

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only